AI Article Synopsis
- The study investigates the specific subtype of muscarinic receptors involved in muscle contractions induced by methacholine in the rabbit iris sphincter by measuring equilibrium dissociation constants (KB) of various antagonists.
- The antagonists showed varying affinities, with results suggesting the presence of an M2 receptor in the muscle, as evidenced by competitive antagonism patterns.
- The findings imply that other muscarinic receptors (M1, M3, M4) are unlikely present, while low affinity values and a specific enantiomeric ratio could indicate the potential involvement of an M5 receptor.
Article Abstract
In order to analyse the subtype of muscarinic receptors involved in the methacholine-induced contraction of the rabbit iris sphincter we have determined equilibrium dissociation constants (KB) of various antagonists in the sphincter muscle. The values were compared with those observed at M1 (rabbit vas deferens), M2 (heteroreceptors in rat iris) and M3 receptors (guinea-pig ileum), or at the muscarinic receptors in the guinea-pig uterus. The methacholine-induced contraction of the uterus from immature guinea-pigs was competitively antagonized by pirenzepine (6.64, -log KB), 4-DAMP (8.39), hexahydrodifenidol (HHD; 7.00 for the (R)- and 5.40 for the (S)-enantiomer), p-fluoro-hexahydrosiladifenidol (p-F-HHSiD; 6.25) and valethamate bromide (8.04). The affinity of the antagonists is consistent with the presence of an M2 receptor. The -log KB values of the antagonists in the rabbit iris sphincter (6.43, p-F-HHSiD; 6.22, AQ-RA 741; 7.23 and 5.34, (R)- and (S)-trihexyphenidyl) were lower than, or within the lowest range of, estimates in the other experimental models, irrespective of the subtype selectivity of the antagonist. This excludes the presence of an M1, M2, M3 or M4 receptor in this smooth muscle. The affinity of UH-AH 37 in the iris was intermediate between that for M1 or M3, and M2 receptors. The low affinity of AQ-RA 741 and the low enantiomeric ratio of trihexyphenidyl (THP) in the iris (77.6) would be compatible with a presumed M5 receptor.(ABSTRACT TRUNCATED AT 250 WORDS)
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00164573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Melanin-Binding-Based Discovery of Topically Instilled Carbonic Anhydrase Inhibitors for Targeted Delivery and Prolonged Action in the Eye.
Mol Pharm
January 2025
School of Pharmacy, University of Eastern Finland, Yliopistonranta 1 C, 70210 Kuopio, Finland.
Glaucoma is a vision-threatening disease that is currently treated with intraocular-pressure-reducing eyedrops that are instilled once or multiple times daily. Unfortunately, the treatment is associated with low patient adherence and suboptimal treatment outcomes. We developed carbonic anhydrase II inhibitors (CAI-II) for a prolonged reduction of intraocular pressure (IOP).
View Article and Find Full Text PDFOcular and Plasma Pharmacokinetics of Sitagliptin Eye Drops: Preclinical Data.
Pharmaceuticals (Basel)
November 2024
Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, 08035 Barcelona, Spain.
Early stages of diabetic retinopathy are currently considered an unmet medical need due to the lack of effective treatments beyond proper monitoring and control of glycemia and blood pressure. Sitagliptin eye drops have emerged as a new therapeutic approach against early stages of the disease, as they can prevent its main hallmarks, including both neurodegeneration and microvascular impairment. Interestingly, all of these effects occur without any glycemic systemic improvement.
View Article and Find Full Text PDFSubconjunctival injection of microcrystalline prodrug of dexamethasone for long-acting anti-inflammation after phacoemulsification surgery.
J Control Release
January 2025
Key Laboratory of Functional Polymer Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin 300071, China. Electronic address:
Article Synopsis
- - Researchers developed a long-acting injectable form of dexamethasone (SKD microcrystals) for treating chronic eye inflammation, comparing its effects to a common eye drop treatment (Maxidex) in a rabbit model after eye surgery.
- - A single subconjunctival injection of SKD MCs effectively reduced inflammation for up to 28 days, while Maxidex only worked for about 7 days, showing SKD's longer-lasting benefits.
- - Both treatments were safe, with SKD MCs demonstrating consistent drug presence in the eye tissues for up to 84 days without raising intraocular pressure or causing retinal damage, indicating promise for future clinical use in eye diseases.
Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys.
Transl Vis Sci Technol
November 2024
Santen Pharmaceutical Co., Ltd., Osaka, Japan.
Purpose: To evaluate the ocular distribution of omidenepag isopropyl (OMDI) and its active form omidenepag (OMD), an EP2 receptor agonist, after topical administration of OMDI into rabbit and monkey eyes, and to determine whether OMDI and OMD interact with target receptors or enzymes of other antiglaucoma agents.
Methods: Both eyes of six rabbits and of 14 monkeys were topically instilled with 0.03% [14C]-OMDI.
Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension.
J Ocul Pharmacol Ther
November 2024
Department of Ophthalmology, University Hospitals UZ Leuven, Leuven, Belgium.
Pharmacokinetic evaluation of ocular penetration and systemic accumulation of preservative-free bimatoprost 0.01% ophthalmic gel (PFB 0.01% gel).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!